Market Overview:
Humira(adalimumab) is a human monoclonal antibody used to treat various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. Biosimilar versions provide cost effective treatment options with comparable safety and efficacy.
Market key trends:
One of the key trends in the humira biosimilar market is the patent expiration of Humira's reference product. AbbVie's patent on Humira expired in major markets like Europe in October 2018 and will expire in the US in December 2023, allowing for biosimilar competition. This has led to several biosimilar approvals and launches by companies like Amgen, Sandoz and Boehringer Ingelheim. Increased biosimilar penetration is expected to substantially reduce treatment costs and expand patient access to biologic therapy for various chronic conditions.
Segment Analysis
The global Humira Biosimilar Market biosimilar market is dominated by the rhematoid arthritis sub-segment. Currently, Humira is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and uveitis. The rheumatoid arthritis sub-segment holds the largest market share as rheumatoid arthritis is the most common chronic inflammatory condition affecting approximately 1% of the adult population globally. Humira has been approved for the treatment of moderate to severe active rheumatoid arthritis.
Key Takeaways
The global Humira biosimilar market is expected to witness high growth, exhibiting CAGR of 25.9% over the forecast period 2023 - 2030, due to increasing prevalence of immune-mediated inflammatory diseases globally.
Regional analysis
The US region currently dominates the global Humira biosimilar market with a share of over 60% in 2023. However, the Asia Pacific region is expected to emerge as the fastest growing market during the forecast period. Countries like China, India, South Korea and Japan are expected to offer lucrative opportunities for market players due to rising healthcare spending and increasing generic penetration in the region.
Key players
Key players operating in the Humira biosimilar market are Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc. Amgen Inc. generated the highest revenue from Humira biosimilars in 2023.
